JPWO2020260898A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020260898A5 JPWO2020260898A5 JP2021577385A JP2021577385A JPWO2020260898A5 JP WO2020260898 A5 JPWO2020260898 A5 JP WO2020260898A5 JP 2021577385 A JP2021577385 A JP 2021577385A JP 2021577385 A JP2021577385 A JP 2021577385A JP WO2020260898 A5 JPWO2020260898 A5 JP WO2020260898A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cell
- composition
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 230000005867 T cell response Effects 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 239000000203 mixture Substances 0.000 claims 15
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 210000004027 cell Anatomy 0.000 claims 7
- 230000002163 immunogen Effects 0.000 claims 7
- 239000013598 vector Substances 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 6
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 5
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 210000001808 exosome Anatomy 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 claims 1
- 230000003389 potentiating effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024197303A JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183396 | 2019-06-28 | ||
| EP19183396.1 | 2019-06-28 | ||
| PCT/GB2020/051558 WO2020260898A2 (en) | 2019-06-28 | 2020-06-26 | Novel cancer antigens and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197303A Division JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022538609A JP2022538609A (ja) | 2022-09-05 |
| JPWO2020260898A5 true JPWO2020260898A5 (https=) | 2023-07-18 |
| JP2022538609A5 JP2022538609A5 (https=) | 2023-07-18 |
Family
ID=67145533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021577385A Pending JP2022538609A (ja) | 2019-06-28 | 2020-06-26 | 新規な癌抗原及び方法 |
| JP2024197303A Pending JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024197303A Pending JP2025032114A (ja) | 2019-06-28 | 2024-11-12 | 新規な癌抗原及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220218807A1 (https=) |
| EP (1) | EP3990007A2 (https=) |
| JP (2) | JP2022538609A (https=) |
| KR (1) | KR20220029560A (https=) |
| CN (2) | CN119119228A (https=) |
| AU (1) | AU2020307943A1 (https=) |
| BR (1) | BR112021026375A2 (https=) |
| CA (1) | CA3141229A1 (https=) |
| IL (1) | IL289205A (https=) |
| MX (1) | MX2021015766A (https=) |
| WO (1) | WO2020260898A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021006941A2 (pt) | 2018-10-19 | 2021-08-31 | The Francis Crick Institute Limited | Antígenos de câncer inovadores e métodos |
| CN118666956A (zh) * | 2019-06-25 | 2024-09-20 | 蒙特利尔大学 | 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途 |
| WO2022229647A1 (en) | 2021-04-28 | 2022-11-03 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2025133007A1 (en) | 2023-12-19 | 2025-06-26 | Enara Bio Limited | Novel cancer antigens and methods |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| WO2025224446A1 (en) | 2024-04-23 | 2025-10-30 | Enara Bio Limited | Novel cancer antigens and methods |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002515734A (ja) | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| US6488931B1 (en) * | 1998-12-17 | 2002-12-03 | Corixa Corporation | Compositions and methods for therapy and diagnosis of ovarian cancer |
| DK1871391T3 (da) | 2005-03-30 | 2012-04-16 | Viroxis | Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling |
| US8921050B2 (en) | 2006-03-17 | 2014-12-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of diagnosing renal cell carcinoma |
| US20090297530A1 (en) * | 2006-05-22 | 2009-12-03 | Feng Wang-Johanning | Herv-k antigens, antibodies, and methods |
| US20080019979A1 (en) | 2006-05-22 | 2008-01-24 | Feng Wang-Johanning | HERV-K Antigens, Antibodies, and Methods |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| WO2014004385A2 (en) * | 2012-06-25 | 2014-01-03 | Board Of Regents, The University Of Texas System | Anti-cancer vaccines |
| EP3563835A4 (en) * | 2016-12-29 | 2020-12-30 | Korea Institute of Science and Technology | NEW EXOSOME-BASED ANTI-CANCER AGENT |
| KR101964124B1 (ko) * | 2017-03-28 | 2019-04-01 | 한국과학기술연구원 | 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도 |
| KR101869518B1 (ko) * | 2018-03-28 | 2018-06-20 | 황인후 | 췌장암 줄기세포의 emt-met 가소성을 이용한 암 치료용 수지상 세포 백신의 제조 방법 |
| CN118666956A (zh) * | 2019-06-25 | 2024-09-20 | 蒙特利尔大学 | 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途 |
-
2020
- 2020-06-26 MX MX2021015766A patent/MX2021015766A/es unknown
- 2020-06-26 WO PCT/GB2020/051558 patent/WO2020260898A2/en not_active Ceased
- 2020-06-26 JP JP2021577385A patent/JP2022538609A/ja active Pending
- 2020-06-26 AU AU2020307943A patent/AU2020307943A1/en not_active Abandoned
- 2020-06-26 CA CA3141229A patent/CA3141229A1/en active Pending
- 2020-06-26 CN CN202410989999.0A patent/CN119119228A/zh active Pending
- 2020-06-26 CN CN202080047135.7A patent/CN114341168A/zh active Pending
- 2020-06-26 KR KR1020217039989A patent/KR20220029560A/ko not_active Ceased
- 2020-06-26 EP EP20735234.5A patent/EP3990007A2/en active Pending
- 2020-06-26 BR BR112021026375A patent/BR112021026375A2/pt not_active IP Right Cessation
-
2021
- 2021-12-17 US US17/644,923 patent/US20220218807A1/en active Pending
- 2021-12-21 IL IL289205A patent/IL289205A/en unknown
-
2024
- 2024-11-12 JP JP2024197303A patent/JP2025032114A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7072467B2 (ja) | 乳癌再発の予防のためのワクチン | |
| JP4185147B2 (ja) | Ｋｄｒペプチド及びこれを含むワクチン | |
| KR101284237B1 (ko) | Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도 | |
| RU2206329C2 (ru) | Иммуностимулятор, вызывающий специфичный к опухоли клеточный иммунный ответ и способ его получения | |
| Colluru et al. | Preclinical and clinical development of DNA vaccines for prostate cancer | |
| JP2018536383A (ja) | 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ | |
| JPWO2007097358A1 (ja) | Ｈｌａ−ａ＊３３０３拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 | |
| JP2014521657A (ja) | 膵臓がんに対する樹状細胞（ｄｃ）ワクチン療法 | |
| Gillespie et al. | The potential of melanoma antigen expression in cancer therapy | |
| CN109970846A (zh) | 一种肿瘤相关抗原XAGE-1b九肽及其应用 | |
| CN106243213B (zh) | 一种肿瘤相关抗原XAGE-1b短肽及应用 | |
| JP2015520129A (ja) | 多価乳がんワクチン | |
| CN101146550A (zh) | 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法 | |
| Llopiz et al. | Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy | |
| CN106279392B (zh) | 肿瘤相关抗原XAGE-1b短肽及其应用 | |
| KR101810840B1 (ko) | 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp) | |
| JP2004527449A (ja) | テロメラーゼ逆転写酵素を用いる癌を治療するための万能ワクチンと方法 | |
| Smith et al. | Immunotherapy of melanoma | |
| JPWO2020260898A5 (https=) | ||
| JPWO2020260897A5 (https=) | ||
| JPWO2021005339A5 (https=) | ||
| JPWO2021005338A5 (https=) | ||
| JPWO2020079448A5 (https=) | ||
| CN106279391B (zh) | 肿瘤相关抗原XAGE-1b短肽及应用 | |
| KR101203979B1 (ko) | Ｒｎａ 전이 항원 제시 세포를 이용한 신규 종양항원의 규명 방법 |